[New therapeutic strategies in non-Hodgkin lymphomas and Hodgkin lymphoma]

Abstract

In this review, we report the main advances of the last years in the four most common lymphomas in France, namely Hodgkin lymphoma, large cell diffuse B lymphoma, follicular lymphoma and mantle cell lymphoma. We have identified consensual practices in first line in France and then distinguished the targeting by new molecules. Thus, we wanted to highlight the problems for each of these four lymphomas and understand the tools used to find solutions. Finally, this review makes it possible to understand to what extent the new molecules (targeted therapies, immunotherapy) make it possible to continuously improve the management of patients with lymphomas. The global dynamics seems to reduce the place of conventional chemotherapies in favor of these new molecules. However, because of the increase in therapeutic possibilities, the challenge remains to find the combination associated with the best risk-benefit ratio.

Keywords: Hodgkin lymphoma; Immunotherapy; Immunothérapie; Lymphome de Hodgkin; Lymphome non hodgkiniens; Non-hodgkin lymphoma; Targeted drugs; Thérapies ciblées.